Antibody-mediated Rejection: Clinical Trials

12 trials for Antibody-mediated Rejection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 active not recruiting, 1 terminated, 1 withdrawn. 12 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 7, Active not recruiting 3, Terminated 1, Withdrawn 1
Phase 13Completed 3

Follow Antibody-mediated Rejection: new trials by email Literature Review of Antibody-mediated Rejection trials Research Report on Antibody-mediated Rejection

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial
Methylprednisolone (MP), Daratumumab, Telitacicept - Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)
Phase 2Active not recruitingFirst Affiliated Hospital, Sun Yat-Sen University202026-06-202026-10-29
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
ALXN2030, Placebo - Antibody-Mediated Rejection, Kidney Transplantation
Phase 2Active not recruitingAlexion Pharmaceuticals, Inc.472025-03-072026-08-11
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe - Antibody-mediated Rejection
Phase 2Active not recruitingargenx332024-08-302026-07-02
Felzartamab in Late Antibody-Mediated Rejection
Felzartamab, Placebo - Antibody-mediated Rejection
Phase 2CompletedFarsad Eskandary222021-10-062024-04-18
Desensitization in Kidney Allograft Using Daratumumab
Daratumumab dose escalation, Daratumumab full dose - Allosensitization, Kidney Transplant Rejection
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris212020-02-182024-03-19
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
Belatacept, Tacrolimus, ATG - Lung Transplant Rejection, Antibody-mediated Rejection
Phase 2CompletedWashington University School of Medicine272019-12-172022-11-25
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
Belatacept, Carfilzomib - Lung Transplant Rejection, Antibody-mediated Rejection
Phase 2WithdrawnDuke University2019-05-012019-05-02
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease
Phase 1 / Phase 2CompletedStanley Jordan, MD202018-02-272026-10-30
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Clazakizumab - Antibody-mediated Rejection, Kidney Transplant; Complications
Phase 1 / Phase 2CompletedStanley Jordan, MD102018-02-212025-05-06
A Pilot Trial of Clazakizumab in Late ABMR
Clazakizumab / Clazakizumab, Placebo / Clazakizumab - Antibody-mediated Rejection
Phase 2CompletedMedical University of Vienna202018-01-162020-09-09
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Bortezomib, Placebo - Late Rejection of Renal Transplant, Antibody-mediated Rejection
Phase 2CompletedMedical University of Vienna442013-12-012017-03-23
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Eculizumab, Immunoglobulin, Plasmapheresis - Antibody-mediated Rejection, Humoral Rejection
Phase 2TerminatedBrigham and Women's Hospital112013-11-012017-09-21

Narrower conditions

Rejection, Psychology (2)  ·  Kidney Failure, Chronic (1)

Broader conditions

Behavior (2)  ·  Social Behavior (2)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Kidney Diseases (1)  ·  Male Urogenital Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Renal Insufficiency (1)  ·  Renal Insufficiency, Chronic (1)  ·  Urogenital Diseases (1)  ·  Urologic Diseases (1)

Interventions

clazakizumab (3)  ·  Abatacept (2)  ·  Methylprednisolone (2)  ·  Saline Solution (2)  ·  Bortezomib (1)  ·  Immunoglobulins (1)  ·  Immunoglobulins, Intravenous (1)  ·  Methylprednisolone Hemisuccinate (1)  ·  Mycophenolic Acid (1)  ·  Plasmapheresis (1)  ·  Prednisone (1)  ·  Sodium Chloride (1)  ·  Tacrolimus (1)  ·  carfilzomib (1)  ·  daratumumab (1)

Sponsors

Medical University of Vienna (2)  ·  Stanley Jordan, MD (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Brigham and Women's Hospital (1)  ·  Duke University (1)  ·  Farsad Eskandary (1)  ·  First Affiliated Hospital, Sun Yat-Sen University (1)  ·  Washington University School of Medicine (1)  ·  argenx (1)

Countries

United States (6)  ·  Austria (4)  ·  Germany (3)  ·  Canada (2)  ·  China (2)  ·  France (2)  ·  Spain (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Czechia (1)  ·  South Korea (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Stanley Jordan, MD (2)  ·  Anil K Chandraker, MD (1)  ·  Bernd Jilma, MD (1)  ·  Laurie Snyder (1)  ·  Marie Matignon, MD (1)  ·  Ramsey R Hachem, MD (1)

Results publications

PMID 24708575, PMID 26281144, PMID 30635033, PMID 31530561, PMID 34153143, PMID 35395951, PMID 36382130, PMID 37322595, PMID 37899481, PMID 38804514, PMID 39134120, PMID 39780312, PMID 40444214, PMID 42855714

NIH funding

2017 (1), 2023 (1)